Your browser doesn't support javascript.
loading
Long-Term Change in Bone Mineral Density in Women Living With HIV: A 10-Year Prospective Controlled Cohort Study.
Macdonald, Heather M; Maan, Evelyn J; Berger, Claudie; Côte, Hélène C F; Murray, Melanie C M; Pick, Neora; Prior, Jerilynn C.
Affiliation
  • Macdonald HM; Active Aging Research Team University of British Columbia Vancouver BC Canada.
  • Maan EJ; Department of Family Practice Faculty of Medicine, University of British Columbia Vancouver BC Canada.
  • Berger C; Oak Tree Clinic, BC Women's Hospital and Health Centre Vancouver BC Canada.
  • Côte HCF; Research Institute of the McGill University Health Centre Montreal QC Canada.
  • Murray MCM; Department of Pathology & Laboratory Medicine University of British Columbia Vancouver BC Canada.
  • Pick N; Centre for Blood Research Faculty of Medicine, University of British Columbia Vancouver BC Canada.
  • Prior JC; Women's Health Research Institute Vancouver BC Canada.
JBMR Plus ; 7(8): e10761, 2023 Aug.
Article in En | MEDLINE | ID: mdl-37614300
ABSTRACT
Women living with HIV (WLWH) may be at higher risk for osteoporosis and fragility fractures. However, limited prospective data describe long-term trajectories of bone mineral density (BMD) in WLWH versus women without HIV. Thus, in this prospective study, we aimed to compare 10-year change in areal BMD (aBMD) between WLWH (n = 49; 36.8 ± 8.8 years; 96% pre/perimenopausal) and HIV-negative women (population-based controls; n = 49; 41.9 ± 9.2 years; 80% pre/perimenopausal). In an exploratory analysis, we compared fracture history between WLWH and controls. Outcomes were lumbar spine (L1 to L4), total hip, and femoral neck aBMD at baseline and follow-up, which occurred at 13 and 10 years in WLWH and controls, respectively. We fit multivariable regression models to compare baseline and 10-year change in aBMD between groups, adjusting for osteoporosis risk factors. Within WLWH, we examined associations between aBMD and HIV-related factors, including combination antiretroviral therapy (cART) duration. WLWH were diagnosed 6.5 ± 3.7 years before baseline, 80% were on cART for 241 ± 142 weeks, and 49% had HIV plasma viral load <40 copies/mL. Before and after adjusting for osteoporosis risk factors, baseline and 10-year change in aBMD did not differ between WLWH and controls at any site. At baseline, more WLWH than controls reported a history of low-trauma fracture (30% versus 10%, p < 0.05) and major osteoporotic fracture (17% versus 4%, p < 0.05). During follow-up, the number of WLWH and controls with incident fragility fracture was not significantly different. Lifetime cART duration and tenofovir use were not associated with aBMD 10-year percent change. Higher CD4 count at baseline was positively associated with femoral neck aBMD 10-year percent change. Long-term aBMD change in this small WLWH cohort paralleled normal aging, with no evidence of influence from cART use; however, these results should be interpreted with caution given the small sample size. Larger cohort studies are needed to confirm these findings. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: JBMR Plus Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: JBMR Plus Year: 2023 Document type: Article